Immediate high‑dose intravenous immunoglobulins followed by direct thrombin‑inhibitor treatment is crucial for survival in Sars‑Covid‑19‑adenoviral vector vaccine‑induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis

Germany, 22 May 2021, Graf et al, Journal of Neurology


A case of a 29-year-old male public health care professional, vaccinated with ChAdOx1 nCov-19, AstraZeneca, complicated by diffuse thrombosis and neurological deficits.

Download PDF

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s